Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal Aβ or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD.

Highlights

  • The neurovascular unit (NVU) is defined as a complex functional and anatomical structure composed of: (a) neurons and interneurons, (b) glial cells such as microglia, astrocytes, and oligodendrocytes, (c) vascular cells such as endothelial cells, pericytes, and smooth muscle cells (SMCs), and (d) a basal lamina formed by brain endothelial cells and extracellular matrix (Figure 1) [1,2]

  • We review the relationship between the NVU and Blood-Brain Barrier (BBB) dysregulation and Alzheimer’s disease (AD) pathology

  • CD36/a3b1-integrin/CD47 complex regulates filamentous amyloid β peptide (Aβ) (fAβ) interaction in microglia cells that the presence of pathological tau has been observed as puncta in perivascular spaces in sporadic AD brains [53]

Read more

Summary

Introduction

The neurovascular unit (NVU) is defined as a complex functional and anatomical structure composed of: (a) neurons and interneurons, (b) glial cells such as microglia, astrocytes, and oligodendrocytes, (c) vascular cells such as endothelial cells, pericytes, and smooth muscle cells (SMCs), and (d) a basal lamina formed by brain endothelial cells and extracellular matrix (Figure 1) [1,2]. Pial arteries (panel (b)) run along the brain surface and depict the different levels of the vascular tree. The second hallmark is the presence gether withβ-peptide astrocytic(Aβ) end-feet, pericytes, microglia, the BBB the circulating of amyloid deposits in theand brain parenchyma andseparates around cerebral blood blood components from neurons [2,33]

(Figures
Cellular and Structural Components of the NVU Along the Cerebrovascular Tree
Overview
Bidirectional Pathological Association between Tau and the NVU and BBB
CAA Acts as a Trigger for Dysfunction of the NVU
Perivascular Microglial Activation
Astrocytic End-Foot Dysfunction
Pericyte Degeneration
Endothelial Cell Degeneration and BBB Breakdown
Neuronal Cell Death Mechanisms
The Two-Hit Vascular Hypothesis and Dysfunction of the NVU
General Limitations in AD Therapy
Therapeutics Associated with the Amyloidogenic Pathway
Drugs Targeting Tau Protein
Therapeutic Strategies Focused on the NVU
Drugs for Maintenance of BBB and NVU Integrity
Recent Approaches for Improving the NVU
Findings
Conclusions and Perspective

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.